Collaboration and License Agreements - Novartis Pharma AG (Details) - USD ($) $ in Thousands		3 Months Ended
	Oct. 23, 2025	Dec. 31, 2025	Dec. 31, 2024	Sep. 30, 2025	Aug. 29, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		$ 264,033	$ 2,500
Contract liabilities included in deferred revenue, current		111,933	0	$ 2,399
Contract liabilities included in deferred revenue, non-current		53,825	$ 0	$ 0
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract liabilities included in deferred revenue, current		111,900
Contract liabilities included in deferred revenue, non-current		53,800
Novartis | Novartis Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 200,000
Enrollment related milestone payments					$ 30,000
Variable consideration	32,000
Total transaction price	$ 232,000
Collaboration agreement termination notice period prior to any regulatory approval of a licensed product					30 days
Collaboration arrangement, written notice period					180 days
Revenue		$ 34,200
Novartis | Novartis Collaboration Agreement | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments					$ 175,000
Sales-related milestone payments					285,000
Novartis | Novartis Collaboration Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments					245,000
Sales-related milestone payments					$ 370,000